Navigation Links
Children's Hospital neurosurgeon receives grant
Date:1/8/2008

Childrens Hospital of Pittsburgh of UPMCs Chief of the Division of Pediatric Neurosurgery Ian F. Pollack, MD, has received a grant from the Childrens Brain Tumor Foundation for his pioneering work in the field of neuro-oncology.

Awarded for his project, Molecular Makers of Outcome in Childhood Oligodendrogliomas, Dr. Pollacks research focuses on a category of brain tumors that he says has previously not been well studied in children.

Were identifying the molecular features of the tumor, which will allow doctors to better tailor a specific treatment for the patient, Dr. Pollack said. For example, we are looking forward to the day when physicians can predict which patients will respond to new therapies and which will benefit from more conventional treatments.

Dr. Pollack said Childrens Hospital has continued to serve as a leader in this type of research because of the continued support of foundations like the Childrens Brain Tumor Foundation. This grant totaled $150,000.

This grant, and others we have received previously, will enable us to explore new areas of brain tumor research at Childrens and broaden our scope on eventual treatments, Dr. Pollack said.

Dr. Pollacks primary research interests focus on identifying and evaluating innovative strategies for classifying and treating malignant brain tumors, improving the treatment of children with brain tumors and optimizing the management of childhood craniofacial disorders. He has been listed in Best Doctors in America and Whos Who in Science and Engineering and has been awarded several research grants from the National Institutes of Health.

Dr. Pollack represents the epitome of the translational researcher and is one of the very few true neurosurgical physician-scientists in the nation, said Amin Kassam, MD, associate professor and chair, Department of Neurological Surgery at the University of Pittsburgh School of Medicine and UPMC. Accordingly, this allows us to remain at the forefront of neuro-oncology in the nation.

In July, Dr. Pollack was awarded $200,000 in funding from the Brain Tumor Society, for his study titled, Predictors of Outcome in Pediatric Low-Grade Astrocytomas. According to Dr. Pollack, this project focuses on the most common type of pediatric brain tumors, but the goal is similar: to better characterize the molecular changes that are associated with tumor development and recurrence, so that treatments can be better targeted to those tumors at high risk for regrowth.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related biology news :

1. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
2. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
3. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
4. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
5. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
6. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
7. Computational mathematical sciences receives NSF grant for undergraduate research
8. K-State specialist in tick-borne pathogens receives $1.8 million grant
9. Liang receives NIH grant for biofilm research
10. CONRAD receives $28.5M Gates Foundation grant for HIV prevention research
11. Univ. of Arizona receives $2.5 million to study Amazon forests and climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , ... Inc. (ESI). Mr. Murray will bring valuable expertise ... experience in leading international business teams. As the National Division Leader, ... uphold Eurofins, status as the global leader in bio-analytical testing services. ... , , ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
Breaking Biology Technology: